What is the history of Hidradenitis Suppurativa?

TL;DR: Hidradenitis Suppurativa, historically known as Acne Inversa or Verneuil’s disease, was first clinically characterized in 1854 by French surgeon Aristide Verneuil. While long misdiagnosed as simple boils or poor hygiene, modern medicine now recognizes Hidradenitis Suppurativa as a complex, chronic inflammatory disease of the hair follicles rather than an infection or a lifestyle-related condition.

When and how was Hidradenitis Suppurativa first described?

The medical history of Hidradenitis Suppurativa dates back to 1854, when the French surgeon Aristide Verneuil first described the condition in scientific literature, leading to its early namesake, Verneuil’s disease. Verneuil observed that the inflammation originated near the apocrine sweat glands, particularly in the axillae (armpits) and groin. For decades, the disease was poorly understood, often confused with simple abscesses or tuberculosis of the skin, which led to significant diagnostic delays for patients.

How has our understanding of the condition evolved?

For much of the 20th century, Hidradenitis Suppurativa was incorrectly attributed to poor hygiene or bacterial infection. It was only through clinical observation and subsequent immunological research that the medical community realized the condition is, in fact, an autoinflammatory disorder. We now understand that the primary pathology involves the occlusion of hair follicles, which triggers a robust immune response. The realization that Hidradenitis Suppurativa is a systemic disease involving the immune, endocrine, and circulatory systems has fundamentally shifted how physicians approach patient care.

What are the major milestones in treatment development?

The management of Hidradenitis Suppurativa has moved from purely surgical interventions to a nuanced, multi-disciplinary approach. Major milestones include:

• Early 20th Century: Reliance on aggressive, often disfiguring surgical excision of affected tissue.


• Mid-20th Century: Introduction of long-term antibiotic therapy to manage secondary bacterial colonization and reduce inflammation.


• 2015: A landmark turning point occurred when Adalimumab (Humira) became the first FDA-approved biologic therapy specifically for the treatment of moderate-to-severe Hidradenitis Suppurativa, marking the first time a systemic immune-modulator was targeted for this condition.


• Modern era: Focus on early detection using the Hurley Staging system (Stages I, II, and III) to prevent the irreversible scarring and sinus tract formation that define advanced disease.

How have technology and genetics changed our perspective?

Modern genomic studies have provided critical insights into the hereditary nature of Hidradenitis Suppurativa. Researchers have identified that approximately 30-40% of patients report a family history of the disease, pointing toward potential genetic markers involving the gamma-secretase complex. This shift from viewing the disease as a "skin problem" to a genetic and systemic inflammatory condition has empowered researchers to investigate targeted therapies that address the underlying molecular drivers rather than just the superficial symptoms.

The evolution of patient advocacy

For many years, the stigma associated with the drainage and odor of Hidradenitis Suppurativa left patients isolated. Today, patient advocacy has transformed the landscape. Communities like DiseaseMaps.org, which supports over 729 members living with this condition, provide a vital space for shared experiences, validating the patient journey, and pushing for faster clinical diagnosis. This collective voice has successfully campaigned for increased research funding and greater awareness among primary care physicians.

Next steps

• Consult a board-certified dermatologist who specializes in inflammatory skin conditions to discuss current biologic and immunosuppressive options.


• Join the DiseaseMaps.org community to connect with others who understand the daily challenges of living with this condition.


• Keep a detailed symptom diary to track flares, which can assist your physician in adjusting your personalized treatment plan.


• Stay informed about emerging clinical trials by monitoring the NIH clinical trials database for new research on targeted cytokines.

Medical disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• NIH Genetic and Rare Diseases Information Center (GARD): Hidradenitis Suppurativa.


• Orphanet: Portal for rare diseases and orphan drugs.


• OMIM (Online Mendelian Inheritance in Man): Entry #142690 (Hidradenitis Suppurativa).


• DiseaseMaps.org: Community insights and patient-reported data.